This recent study used small molecules that selectively disrupted the interaction of NFAT and AP‐1 without inhibiting their binding to the target promoter, or other small molecules interacted with the transcription factors DNA binding to the IL‐2 promoter indicating that targeting transcription factor could represent new avenues to treat human diseases like allergic asthma without having the generalized immunosuppressive effects of cyclosporin A. In this study, we extended the findings of the upregulation of NFATc1 to different cohorts of children at primary school age. This evidence concerns the gene IL2 and allergic asthma.